Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy
Epilepsia Open · 2024
DOI: 10.1002/epi4.12857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, 2024. Verfasst von Judit Catalán-Aguilar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institut d'Investigació en Psicologia dels Recursos Humans, del Desenvolupament Organitzacional i de la Qualitat de Vida Laboral (Idocal)/Department …. Hauptthemen laut MEDLINE: Epilepsies, Partial, Epilepsy, Carbamates, Chlorophenols. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Generalitat Valenciana, MCIN/AEI/10.13039/501100011033.
Abstract (Originalsprache)
Objective
Cenobamate is a recently approved antiseizure medication that proved to be safe and effective in randomized controlled trials. However, little is known about its impact on some areas frequently affected by epilepsy. For this reason, we explored the effects of cenobamate on cognitive performance, as well as on negative affectivity and quality of life in a sample of patients with drug‐resistant epilepsy.
Methods
Two prospective cohort studies were carried out. In Study 1, 32 patients (22 men and 10 women) underwent a baseline (T0) and a short‐term (T1) neuropsychological assessment after 3 months of cenobamate administration. In Study 2, 22 patients (16 men and 6 women) from the T1 sample also underwent a baseline and a follow‐up evaluation (T2) 6 months after T0.
Results
No significant differences were found in cognitive variables, negative affectivity, and quality of life either in Study 1 or Study 2. Similarly, based on the reliable change index, it was found that most patients showed no changes in these variables. Significance These results suggest that cenobamate is a safe antiseizure medication in terms of cognition, negative affectivity, or quality of life since no adverse events have been found after 3 and 6 months of treatment. Plain Language Summary Cenobamate is a new antiseizure medication. In patients with epilepsy, cenobamate seems to not affect cognition, anxiety, depression, or quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut d'Investigació en Psicologia dels Recursos Humans, del Desenvolupament Organitzacional i de la Qualitat de Vida Laboral (Idocal)/Department of Psychobiology, Psychology Center, Universitat de València. Av. Blas…
- Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, Hospital Universitario y Politécnico La Fe. Av. Fernando Abril Martorell, Valencia, Spain.
- Faculty of Health Sciences, Valencian International University, Valencia, Spain.
- Department of Psychology, Universidad Europea de Valencia, Valencia, Spain.
- Faculty of Health Sciences, Universidad Isabel I, Burgos, Spain.
ORCID-Profile: Judit Catalán-Aguilar, Kevin G Hampel, Irene Cano-López, Alejandro Lozano-García, Paula Tormos-Pons, Esperanza González-Bono, Vicente Villanueva
Förderung
- Generalitat Valenciana
- MCIN/AEI/10.13039/501100011033
Zitieren
APA
Catalán-Aguilar, J., Hampel, K. G., Cano-López, I., Garcés, M., Lozano-García, A., Tormos-Pons, P., González-Bono, E., & Villanueva, V. (2024). Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy. Epilepsia Open. https://doi.org/10.1002/epi4.12857
Vancouver
Catalán-Aguilar J, Hampel KG, Cano-López I, Garcés M, Lozano-García A, Tormos-Pons P, et al. Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy. Epilepsia Open. 2024. doi:10.1002/epi4.12857
BibTeX
@article{CatalnAguilar2024,
author = {Catalán-Aguilar, Judit and Hampel, Kevin G and Cano-López, Irene and Garcés, Mercedes and Lozano-García, Alejandro and Tormos-Pons, Paula and González-Bono, Esperanza and Villanueva, Vicente},
title = {Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy},
journal = {Epilepsia Open},
year = {2024},
doi = {10.1002/epi4.12857}
}
EUVIMED